Cytosorbents Corp (CTSO) CEO Sells $85,936.95 in Stock

Share on StockTwits

Cytosorbents Corp (NASDAQ:CTSO) CEO Phillip P. Chan sold 5,787 shares of the firm’s stock in a transaction on Wednesday, September 5th. The shares were sold at an average price of $14.85, for a total transaction of $85,936.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Phillip P. Chan also recently made the following trade(s):

  • On Friday, September 7th, Phillip P. Chan sold 11,418 shares of Cytosorbents stock. The shares were sold at an average price of $14.65, for a total transaction of $167,273.70.

NASDAQ CTSO traded down $0.10 during midday trading on Friday, hitting $14.10. The company had a trading volume of 186,200 shares, compared to its average volume of 251,808. The company has a debt-to-equity ratio of 0.46, a current ratio of 8.82 and a quick ratio of 8.60. The firm has a market capitalization of $465.60 million, a price-to-earnings ratio of -44.06 and a beta of 0.15. Cytosorbents Corp has a fifty-two week low of $5.25 and a fifty-two week high of $14.95.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Thursday, August 2nd. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The company had revenue of $5.76 million during the quarter, compared to analyst estimates of $5.08 million. Cytosorbents had a negative return on equity of 100.51% and a negative net margin of 74.60%. sell-side analysts expect that Cytosorbents Corp will post -0.56 earnings per share for the current fiscal year.

A number of research firms recently issued reports on CTSO. BidaskClub lowered shares of Cytosorbents from a “buy” rating to a “hold” rating in a research note on Friday, August 10th. Maxim Group restated a “buy” rating and issued a $18.00 price target on shares of Cytosorbents in a research report on Tuesday. Cowen restated a “buy” rating and issued a $15.00 price target on shares of Cytosorbents in a research report on Friday, August 3rd. Finally, ValuEngine upgraded shares of Cytosorbents from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 12th. Four equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $14.56.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its position in Cytosorbents by 181.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 83,148 shares of the medical research company’s stock worth $948,000 after purchasing an additional 53,642 shares during the last quarter. MetLife Investment Advisors LLC acquired a new stake in Cytosorbents in the 2nd quarter worth $169,000. Metropolitan Life Insurance Co. NY acquired a new stake in Cytosorbents in the 2nd quarter worth $119,000. PEAK6 Investments L.P. bought a new position in shares of Cytosorbents during the 2nd quarter worth about $168,000. Finally, Manatuck Hill Partners LLC lifted its holdings in shares of Cytosorbents by 4.9% during the 2nd quarter. Manatuck Hill Partners LLC now owns 258,200 shares of the medical research company’s stock worth $2,943,000 after acquiring an additional 12,000 shares during the period. Institutional investors own 24.91% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.

Featured Article: Earnings Per Share

Insider Buying and Selling by Quarter for Cytosorbents (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply